Dorsey Wright & Associates Tcr2 Therapeutics Inc. Transaction History

Dorsey Wright & Associates

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 27, 2021	SELL	$20.38 - $34.07 $11,514 - $19,249	-565 Closed	0 $0
Q4 2020 Jan 28, 2021	BUY	$19.0 - $32.63 $2,679 - $4,600	141 Added 33.25%	565 $17,000
Q3 2020 Oct 28, 2020	BUY	$13.1 - $20.69 $5,554 - $8,772	424 New	424 $9,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

Stay updated on Dorsey Wright & Associates with notifications on news.